Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

Shipments to China are now paused through the end of 2025, dragging global sales of the HPV vaccine down 55% last quarter.

MSD is slashing $3bn (€2.59bn) from its annual spending as it braces for off-brand competition to its Irish-manufactured ...

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

Merck (MRK) is cutting $3 billion from its annual expenses as it prepares for generic competition to its blockbuster cancer drug, Keytruda.

Merck and Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world.

We recently published 13 Stocks That Jim Cramer Recently Talked About. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed.

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...

Merck & Co said on Tuesday it was extending its hold on Gardasil shipments to China until at least the end of 2025 due to ...